SCHEMBL60079

SCHEMBL60079

c1ccc(N2CCCCC2)nc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 1/20 0.66
KDM4E B2RXH2 4/20 0.62
CNR2 P34972 2/20 0.62
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55
GRIN2B Q13224 1/20 0.55
GRIN2C Q14957 1/20 0.55
GRIN3A Q8TCU5 1/20 0.55
ALDH1A1 P00352 6/20 0.54
HSD17B10 Q99714 3/20 0.54
USP2 O75604 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 2/20 0.54
TSHR P16473 2/20 0.54
CYP2C19 P33261 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19540186 1.00 PLD1 (0.66) PLD1KDM4ECNR2GRIN2DGRIN3B
SCHEMBL29389926 1.00 PLD1 (0.66) PLD1KDM4ECNR2GRIN2DGRIN3B
SCHEMBL3154137 1.00 PLD1 (0.66) PLD1KDM4ECNR2GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL10642748 0.98 PLD1 (0.63) PLD1KDM4ECNR2GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL30864277 0.98 PLD1 (0.63) PLD1KDM4ECNR2GRIN2DGRIN3B
Lithium SCHEMBL31260780 0.98 PLD1 (0.63) PLD1KDM4ECNR2GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL27844704 0.98 PLD1 (0.63) PLD1KDM4ECNR2GRIN2DGRIN3B
SCHEMBL29462629 0.98 PLD1 (0.68) PLD1KDM4ECNR2GRIN2DGRIN3B
SCHEMBL230367 0.98 PLD1 (0.68) PLD1KDM4ECNR2GRIN2DGRIN3B
SCHEMBL18228078 0.98 PLD1 (0.68) PLD1KDM4ECNR2GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746966-A1 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2026-05-27 EP claimed
US-20250221977-A1 NOVEL BENZOTHIOPHENE DERIVATIVE AND USE THEREOF AS BET INHIBITOR BENOBIO CO., LTD. (KR) 2025-07-10 US claimed
WO-2025021236-A1 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) 2025-01-30 WO claimed
WO-2023195669-A1 NOVEL BENZOTHIOPHENE DERIVATIVE AND USE THEREOF AS BET INHIBITOR 주식회사 베노바이오 2023-10-12 WO claimed
EP-4175633-A1 THIENO[3,4-C]PYRAZOL-3-YL ACETAMIDES AS AUTOTAXIN INHIBITORS Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) 2023-05-10 EP claimed
CN-115776907-A MTORC1 modulators and uses thereof 艾奥维安制药公司 2023-03-10 CN claimed
WO-2022003377-A1 THIENO[3,4-C]PYRAZOL-3-YL ACETAMIDES AS AUTOTAXIN INHIBITORS UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2022-01-06 WO claimed
EP-2507239-B1 AZACYCLIC SPIRO DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-03-13 EP claimed
CN-109161028-A It is a kind of using Cucurbituril as the preparation method of the degradable type two-dimension polymer of structural unit 四川大学 2019-01-08 CN claimed
EP-3077380-B1 THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE SANOFI SA (FR) 2018-07-25 EP claimed
WO-2006128097-A1 NUCLEOPHILIC HETEROCYCLIC CARBENE DERIVATIVES OF PD(ACAC)2 FOR CROSS-COUPLING REACTIONS PROMERUS LLC (US) 2006-11-30 WO claimed
EP-1708718-A1 TRIAZOLE DERIVATIVES WHICH INHIBIT VASOPRESSIN ANTAGONISTIC ACTIVITY Pfizer Limited (GB) 2006-10-11 EP claimed
WO-2005079808-A1 TRIAZOLE DERIVATIVES WHICH INHIBIT VASOPRESSIN ANTAGONISTIC ACTIVITY PFIZER LIMITED (GB) 2005-09-01 WO claimed
EP-0783486-B1 NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS DU PONT PHARM CO (US) 1999-10-13 EP claimed
US-5932586-A ANTIINFLAMMATORY AGENTS; ANTIPYRETICS DUPONT PHARMACEUTICALS COMPANY (US) 1999-08-03 US claimed
CN-1166167-A Novel prostaglandin synthase inhibitors DU PONT MERCK PHARMA (US) 1997-11-26 CN claimed
EP-0783486-A1 NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-07-16 EP claimed
US-5593994-A ANTIINFLAMMATORY AGENTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-01-14 US claimed
US-5591881-A DEGRADING TRIALKYLSILYL PROTECTED-THREONINE WITH NINHYDRIN; PERFORMING HONOR-WORDSWORTH-EMONS REACTION CHOONGWAE PHARMACEUTICAL CO., LTD. (KR) 1997-01-07 US claimed
WO-1996010012-A1 NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-04-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221977-A1 NOVEL BENZOTHIOPHENE DERIVATIVE AND USE THEREOF AS BET INHIBITOR BET1, BRD4, BRD1 PLD1 3997/4885KDM4E 229/4885CNR2 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.